Welcome to our dedicated page for SS Innovations news (Ticker: SSII), a resource for investors and traders seeking the latest updates and insights on SS Innovations stock.
SS Innovations International Inc. (Nasdaq: SSII) is a commercial-stage surgical robotics company that develops the SSi Mantra surgical robotic system and SSi Mudra surgical instruments. Company news frequently highlights progress toward its stated goal of making robotic surgery more affordable and accessible to a larger segment of the global population.
News updates for SSII often cover developments related to the SSi Mantra platform, including new installations, clinical milestones, and telesurgery achievements. The company has reported thousands of surgical procedures performed using the SSi Mantra, including cardiac procedures and telesurgeries across categories such as pediatric, urology, gynecology, oncology, and general surgery. Announcements have also described the introduction of smaller 5-millimeter instruments designed for pediatric, cardiac, and head and neck surgery, as well as the use of the SSi Mantra Tele Surgeon Console for remote procedures.
Investors and healthcare professionals following SS Innovations can expect news on quarterly and annual financial results, including revenue from system sales, instrument sales, warranty sales, and lease income. Regulatory and clinical updates are another recurring theme, such as the completion of a human factors validation study for the SSi Mantra at Johns Hopkins Hospital and the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration for multiple specialty indications.
This news feed aggregates press releases, SEC-related announcements, and other public communications from SS Innovations. It provides a single location to review updates on product developments, clinical experience, regulatory milestones, and corporate events related to SSII and its surgical robotic technologies.
SS Innovations has announced that its SSi Mantra Surgical Robotic System has been used to perform over 100 robotic cardiac surgeries, signaling significant market expansion. The SSi Mantra, featuring a unique fifth arm capability, has been utilized in more than 1000 procedures globally. The company anticipates FDA and CE Mark approvals by early 2025, further enhancing its market position. The global cardiac surgery device market is projected to grow from $17.1 billion in 2023 to $24.9 billion by 2030, while the surgical robotics market is expected to increase from $78.8 billion in 2022 to $188.8 billion by 2032. SS Innovations, through its comprehensive robotic cardiac surgery program, aims to provide less invasive, lower cost, and superior outcomes for patients worldwide.
SS Innovations International, Inc. (SSII) achieved a significant milestone by successfully performing the first infant pyeloplasty using its flagship SSi Mantra Surgical Robotic System. The procedure, led by Dr. Chandra Mohan Vaddi in Hyderabad, India, was a success on a 12-month-old baby. The SSi Mantra is the first surgical system made in India and is cost-effective with regulatory approval in India, Guatemala, and Indonesia. The system has been used in over 1000 surgical procedures across various specialties. SS Innovations is seeking regulatory approval in the US and EU by late 2024 or 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.